Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

Several other equities analysts have also commented on the company. Oppenheimer dropped their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 24th. Finally, Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.14.

Perspective Therapeutics Stock Down 4.5 %

Perspective Therapeutics stock opened at $2.35 on Tuesday. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05. The stock’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $7.91.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CATX. FMR LLC increased its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth approximately $4,132,000. State Street Corp increased its stake in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Octagon Capital Advisors LP increased its stake in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after acquiring an additional 800,000 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.